Skip to content
Triangle logo TriangleGet started
← Adenoid Cystic Carcinoma

NCT05010629 · STUDY IN CONTEXT

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.

According to the protocol, all evaluable patients were combined for the primary analysis.

→

secondary · POSTED

PFS based on Kaplan-Meier is defined as the time from registration to the earlier of progressive disease (PD) or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.

→

secondary · POSTED

Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.

Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.

→

secondary · POSTED

DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.

Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The analysis dataset is comprised of all participants with measurable disease at baseline who achieved objective response on treatment. No responders among Part I participants.

→

secondary · POSTED

Number of participants with treatment-related AE is defined as the number of participants who experienced at least one AE assessed as possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.

→

secondary · POSTED

UW-QOL Global Question 1 assessed how participants felt relative to before they developed their cancer. The mean score was calculated among all participants who provided a response to this question. Responses were recorded on a 5-point ordinal scale and transformed to a 0-100 score, where 0 = Much worse, 25 = Somewhat worse, 50 = About the same, 75 = Somewhat better, and 100 = Much better.

Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

Unnamed quality-of-life measure · Mean Score of Global Question 1 in University of Washington Quality of Life Questionnaire (UW-QOL)

Score direction: Not stated by the study. Direction is never inferred from an instrument name.

release id
clinical-indications-draft-1
disease state id
ds-adenoid-cystic-carcinoma
nct id
NCT05010629
qol key
qol-0005
source section id
NCT05010629-om-0005
source outcome index
5
instrument
Unnamed quality-of-life measure
instrument basis
matched 'quality of life' in the study's own wording
scale title
Mean Score of Global Question 1 in University of Washington Quality of Life Questionnaire (UW-QOL)
measure definition
UW-QOL Global Question 1 assessed how participants felt relative to before they developed their cancer. The mean score was calculated among all participants who provided a response to this question. Responses were recorded on a 5-point ordinal scale and transformed to a 0-100 score, where 0 = Much worse, 25 = Somewhat worse, 50 = About the same, 75 = Somewhat better, and 100 = Much better.
time frame
Baseline and off-treatment (end-of-treatment) assessment; maximum treatment duration was 15.6 months.
analysis role
secondary
reporting status
POSTED
higher is better
Source null
direction quote
Source null
population note
Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
Open the exact result →
Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-adenoid-cystic-carcinoma
nct id
NCT05010629
trial label
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
applicability
narrower
applicability note
Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
registry-condition-search
discovery note
Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count
6
harms Count
2
qol Count
1
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0000
    source section id
    NCT05010629-om-0000
    source outcome index
    0
    endpoint
    Objective Response Rate (ORR)
    endpoint definition
    ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.
    time origin
    Tumor assessments were performed every 3 cycles (each cycle was 21 days), for up to 15.6 months.
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    According to the protocol, all evaluable patients were combined for the primary analysis.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0001
    source section id
    NCT05010629-om-0001
    source outcome index
    1
    endpoint
    Median Progression Free Survival (PFS)
    endpoint definition
    PFS based on Kaplan-Meier is defined as the time from registration to the earlier of progressive disease (PD) or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.
    time origin
    Tumor assessments were performed every 9 weeks for up to 20.2 months.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0002
    source section id
    NCT05010629-om-0002
    source outcome index
    2
    endpoint
    Median Overall Survival (OS)
    endpoint definition
    Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant.
    time origin
    Up to 38.1 months
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0003
    source section id
    NCT05010629-om-0003
    source outcome index
    3
    endpoint
    Duration of Response (DOR)
    endpoint definition
    DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated.
    time origin
    Tumor assessments were performed every 3 cycles (each cycle was 21 days), for up to 15.6 months.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The analysis dataset is comprised of all participants with measurable disease at baseline who achieved objective response on treatment. No responders among Part I participants.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0004
    source section id
    NCT05010629-om-0004
    source outcome index
    4
    endpoint
    Number of Participants With Treatment Related Adverse Events (AE)
    endpoint definition
    Number of participants with treatment-related AE is defined as the number of participants who experienced at least one AE assessed as possibly, probably, or definitely related to study treatment according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
    time origin
    AEs were assessed at Day 1 and Day 4 of each 21-day treatment cycle; assessed for up to 16.6 months.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0005
    source section id
    NCT05010629-om-0005
    source outcome index
    5
    endpoint
    Mean Score of Global Question 1 in University of Washington Quality of Life Questionnaire (UW-QOL)
    endpoint definition
    UW-QOL Global Question 1 assessed how participants felt relative to before they developed their cancer. The mean score was calculated among all participants who provided a response to this question. Responses were recorded on a 5-point ordinal scale and transformed to a 0-100 score, where 0 = Much worse, 25 = Somewhat worse, 50 = About the same, 75 = Somewhat better, and 100 = Much better.
    time origin
    Baseline and off-treatment (end-of-treatment) assessment; maximum treatment duration was 15.6 months.
    analysis role
    secondary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Evaluable Patients Popupulation
    regimen
    Participants will receive: Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 in participants enrolled in Part II (lead-in therapy). 9-ING-41 twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    32
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0001
    arm key
    OG000
    arm label
    9-ING-41 + Carboplatin (Part I)
    regimen
    Participants will receive: 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Pembrolizumab + 9-ING-41 + Carboplatin (Part II)
    regimen
    Participants will receive: Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy). 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0001#groups/OG001
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0002
    arm key
    OG000
    arm label
    9-ING-41 + Carboplatin (Part I)
    regimen
    Participants will receive: 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0002#groups/OG000
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Pembrolizumab + 9-ING-41 + Carboplatin (Part II)
    regimen
    Participants will receive: Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy). 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0002#groups/OG001
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0003
    arm key
    OG000
    arm label
    Pembrolizumab + 9-ING-41 + Carboplatin (Part II)
    regimen
    Participants will receive: Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy). 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    3
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0003#groups/OG000
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0004
    arm key
    OG000
    arm label
    9-ING-41 + Carboplatin (Part I)
    regimen
    Participants will receive: 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0004#groups/OG000
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0004
    arm key
    OG001
    arm label
    Pembrolizumab + 9-ING-41 + Carboplatin (Part II)
    regimen
    Participants will receive: Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy). 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0004#groups/OG001
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0005
    arm key
    OG000
    arm label
    9-ING-41 + Carboplatin (Part I)
    regimen
    Participants will receive: 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0005#groups/OG000
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    outcome key
    om-0005
    arm key
    OG001
    arm label
    Pembrolizumab + 9-ING-41 + Carboplatin (Part II)
    regimen
    Participants will receive: Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle (±3 days) for Cycles 1 and 2 (lead-in therapy). 9-ING-41 administered twice per 21-day cycle on Day 1 and Day 4 for up to 1 year. Treatment with 9-ING-41 may continue beyond 1 year in participants with ongoing clinical benefit. Carboplatin administered once per 21-day cycle on Day 1 for up to 1 year.
    analyzed count
    16
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT05010629-om-0005#groups/OG001
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    harm key
    EG000
    source section id
    NCT05010629-ae
    event group key
    EG000
    event group label
    9-ING-41 + Carboplatin (Part I)
    serious affected
    10
    serious at risk
    16
    other affected
    16
    other at risk
    16
    frequency threshold
    0
    collection period
    Adverse events were followed up to 16.6 months. Survival status was followed up to 38.1 months.
    event definition
    Serious adverse events (SAEs) include: death; life-threatening events (immediate risk of death); events requiring or prolonging hospitalization; persistent/significant disability; congenital anomalies; important medical events that may jeopardize the participant or require intervention to prevent serious outcomes; and suspected transmission of infectious agents via the study drug. All other remaining AEs were included in other adverse events (OAEs).
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    harm key
    EG001
    source section id
    NCT05010629-ae
    event group key
    EG001
    event group label
    Pembrolizumab + 9-ING-41 + Carboplatin (Part II)
    serious affected
    8
    serious at risk
    16
    other affected
    16
    other at risk
    16
    frequency threshold
    0
    collection period
    Adverse events were followed up to 16.6 months. Survival status was followed up to 38.1 months.
    event definition
    Serious adverse events (SAEs) include: death; life-threatening events (immediate risk of death); events requiring or prolonging hospitalization; persistent/significant disability; congenital anomalies; important medical events that may jeopardize the participant or require intervention to prevent serious outcomes; and suspected transmission of infectious agents via the study drug. All other remaining AEs were included in other adverse events (OAEs).
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-adenoid-cystic-carcinoma
    nct id
    NCT05010629
    qol key
    qol-0005
    source section id
    NCT05010629-om-0005
    source outcome index
    5
    instrument
    Unnamed quality-of-life measure
    instrument basis
    matched 'quality of life' in the study's own wording
    scale title
    Mean Score of Global Question 1 in University of Washington Quality of Life Questionnaire (UW-QOL)
    measure definition
    UW-QOL Global Question 1 assessed how participants felt relative to before they developed their cancer. The mean score was calculated among all participants who provided a response to this question. Responses were recorded on a 5-point ordinal scale and transformed to a 0-100 score, where 0 = Much worse, 25 = Somewhat worse, 50 = About the same, 75 = Somewhat better, and 100 = Much better.
    time frame
    Baseline and off-treatment (end-of-treatment) assessment; maximum treatment duration was 15.6 months.
    analysis role
    secondary
    reporting status
    POSTED
    higher is better
    Source null
    direction quote
    Source null
    population note
    Arms are defined by treatment assignment. Adenoid cystic carcinoma (ACC) and non-ACC represent disease subgroups within each treatment arm and were not assigned to separate treatment arms. Therefore, participants are reported according to treatment assignment rather than histologic subtype. The number analyzed for each row reflects the number of participants who completed the question at the corresponding time point
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
setting source links

    Preserved source evidence · Not medical advice